Cliff Asness's ACRS Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 60,259 shares of Aclaris Therapeutics, Inc. (ACRS) worth $318,771, representing 0.00% of the portfolio. First purchased in 2017-Q2, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in ACRS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 612,205 shares. Largest reduction occurred in Q3 2024, reducing 386,177 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Aclaris Therapeutics (ACRS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Aclaris Therapeutics (ACRS) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -12,149 | Reduce 16.78% | 60,259 | $5.29 |
| Q1 2026 | -31,384 | Reduce 30.24% | 72,408 | $3.75 |
| Q4 2025 | +68,840 | Add 196.96% | 103,792 | $3.01 |
| Q3 2025 | +34,952 | New Buy | 34,952 | $1.90 |
| Q3 2024 | -386,177 | Sold Out | 0 | $0.00 |
| Q2 2024 | -226,028 | Reduce 36.92% | 386,177 | $1.10 |
| Q1 2024 | +612,205 | New Buy | 612,205 | $1.24 |
| Q2 2023 | -19,968 | Sold Out | 0 | $0.00 |
| Q1 2023 | +5,632 | Add 39.29% | 19,968 | $8.09 |
| Q4 2022 | +3,174 | Add 28.44% | 14,336 | $15.75 |
| Q3 2022 | +410 | Add 3.81% | 11,162 | $15.77 |
| Q2 2022 | -64 | Reduce 0.59% | 10,752 | $13.95 |
| Q1 2022 | -9,119 | Reduce 45.74% | 10,816 | $17.20 |
| Q4 2021 | -39,761 | Reduce 66.61% | 19,935 | $14.55 |
| Q3 2021 | +29,433 | Add 97.26% | 59,696 | $18.01 |
| Q2 2021 | +30,263 | New Buy | 30,263 | $17.55 |
| Q4 2017 | -10,625 | Sold Out | 0 | $0.00 |
| Q3 2017 | -200 | Reduce 1.85% | 10,625 | $25.79 |
| Q2 2017 | +10,825 | New Buy | 10,825 | $27.16 |
Cliff Asness's Aclaris Therapeutics Investment FAQs
Cliff Asness first purchased Aclaris Therapeutics, Inc. (ACRS) in Q2 2017, acquiring 10,825 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Aclaris Therapeutics, Inc. (ACRS) for 19 quarters since Q2 2017.
Cliff Asness's largest addition to Aclaris Therapeutics, Inc. (ACRS) was in Q1 2024, adding 612,205 shares worth $759,134.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 60,259 shares of Aclaris Therapeutics, Inc. (ACRS), valued at approximately $318,771.
As of the Q2 2026 filing, Aclaris Therapeutics, Inc. (ACRS) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Aclaris Therapeutics, Inc. (ACRS) was 612,205 shares, as reported at the end of Q1 2024.